Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Top largecap stocks that mutual funds bought in June included Asian Paints, Trent, Bajaj Finserv, Infosys, and Bharti Airtel, ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

Nifty rose above 25,100 and Sensex gained 76 points, recovering from earlier losses led by sectoral strength.Stock-Specific ...

Kiran Mazumdar-Shaw assessed the readiness of the Hebbagodi Metro Station with BMRCL officials, expressing enthusiasm for the ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Mutual funds pumped Rs 154 billion into Indian equities in June 2025, signalling strong market confidence. Top buys included ...